Prior authorisation (revision 21)
Old revision·03:23, 10 Oct 2025·GHK_Gwendolen
| Prior authorisationInsurance and coverage | |
|---|---|
| Also called | Pre-authorisation, pre-approval |
| Decided by | The payer, not the prescriber |
| Common criteria | Body-mass index, comorbidity, prior therapy |
| Topic infobox · conventions | |
Prior authorisation is a requirement imposed by a payer that a prescription be approved before it will be covered. It is a coverage mechanism rather than a clinical one, and the decision is made by the payer against its own criteria.[1]
For incretin therapies it is close to universal where these drugs are covered at all, and the criteria commonly include a body-mass index threshold, a comorbidity, documented prior attempts at other management, and sometimes a requirement to try a specified alternative first.[1]
Its effect on access is substantial. Requirements add delay, administrative burden on prescribers, and a failure mode in which coverage is denied for a prescription a clinician judged appropriate.[2]
How it operates
[edit]A prescriber submits a request with supporting documentation; the payer assesses it against published or unpublished criteria; approval, denial, or a request for further information follows. Denials may be appealed, in a process with its own timelines.[2]
Step therapy — a requirement to have tried and failed a specified alternative — is a common form. Its rationale is cost containment; its cost is delay and, where the specified alternative is less effective, a period of less effective treatment.[1]
Reauthorisation is often required periodically, sometimes conditional on documented response such as a minimum weight reduction. A person who responds moderately may therefore lose coverage.[2]
Consequences
[edit]| Consequence | Direction |
|---|---|
| Delay to treatment | Days to months |
| Administrative burden | Falls on prescribers and staff |
| Denial despite clinical judgement | Occurs; appealable |
| Discontinuation on coverage change | Common; see Weight regain after discontinuation |
| Migration to unregulated supply | Documented in community reporting |
The last row is where this intersects with the rest of the wiki. Where a licensed product is unaffordable or coverage is denied, some people obtain material outside licensed channels, with the identity, content and sterility uncertainties this wiki documents throughout.[3]
That is a description of an observed pattern, not an endorsement of it. Research-use compounds are not approved for human administration.[4]
Variation
[edit]Prior authorisation is a feature of insurance-based systems and is largely absent where medicines are supplied through a national formulary, which uses different mechanisms — inclusion decisions, prescribing criteria, and volume controls — to the same cost-containment end. See Formulary tier.[1]
Coverage of weight-management indications differs from coverage of diabetes indications for the same molecule in many systems, so status can depend on the indication rather than the drug.[2]
International differences in coverage are one component of the broader pattern described at Global access disparity.[1]
See also
- Insurance coverage of GLP-1 drugs
- Formulary tier
- Cost per milligram
- Global access disparity
- Telehealth prescribing
References
- ^ a b c d e American Diabetes Association. "Standards of Care in Diabetes." Diabetes Care 47(Suppl 1) (2024).
- ^ a b c d Kyle TK, Stanford FC. "Moving toward health policy that respects both science and people living with obesity." Nursing Clinics of North America 56(4):635–645 (2021). PMID 34749900.
- ^ PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see Project:Sourcing guidelines).
- ^ United States Pharmacopeia, General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances.